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Background: Squamous cell carcinoma (SCC) is the most common type of tongue and larynx cancer and a
common type of lung cancer. In this study, we attempted to specifically evaluate the signaling pathway underlying
HGF/Met induced EGFR ligand release in SSCs. The Met proto-oncogene encodes for a tyrosine kinase receptor
which is often hyperactivated in human cancers. Met activation correlates with poor patient outcome. Several studies
revealed a role of Met in receptor-crosstalk inducing either activation of other receptors, or inducing their resistance to
targeted cancer treatments. In an epithelial tumor cell line screen we recently showed that the Met ligand HGF blocks
the EGFR tyrosine kinase and at the same time activates transcriptional upregulation and accumulation in the supernatant
of the EGFR ligand amphiregulin (Oncogene 32:3846–56, 2013). In the present work we describe the pathway responsible
for the amphiregulin induction.
Findings: Amphiregulin is transcriptionally upregulated and is released into the supernatant. We show that Erk2 but not
Erk1 mediates amphiregulin upregulation upon treatment with monocyte derived HGF. A siRNA knockdown of Erk2
completely abolishes amphiregulin release in squamous cell carcinomas.
Conclusions: These results identify Erk2 as the key downstream signal transducer between Met activation and EGFR
ligand upregulation in squamous cell carcinoma cell lines derived from tongue, larynx and lung.
Keywords: Erk2, Met, EGFR, Receptor-crosstalkFindings
A common feature of many human epithelial cancers is
a constitutive activation of the Ras/Raf/MEK/Erk signal
transduction pathway [1-4]. This hyperactivation can be
either induced via activating mutations in members of
this pathway or via binding of extracellular signaling
molecules to a receptor on the cell-surface. These extra-
cellular signaling molecules include cytokines, extracellular
matrix components, GPCR ligands, neurotransmitters and
growth factors. Growth factors bind to specific cell-surface
receptors harboring intrinsic protein kinase activity, the so
called receptor tyrosine kinases (=TK). Following ligand
binding, growth-factor receptor tyrosine kinases such as
Met, the EGF receptor family, the fibroblast growth factor
receptor family or the vascular endothelial growth factor
receptor family become activated and recruit intracellular
adaptor proteins to the cytoplasmic tails of the activated* Correspondence: ullrich@biochem.mpg.de
†Equal contributors
Department of Molecular Biology, Max Planck Institute of Biochemistry, Am
Klopferspitz 18, D-82152, Martinsried, Germany
© 2015 Gusenbauer et al.; licensee BioMed Ce
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.receptors. A signaling cascade is triggered involving Ras,
Raf and MEK. Activated MEK activates the extracellular
signal regulated kinases 1 and 2 (Erk1/2) by phosphoryl-
ation of Threonine and Tyrosine residues within their
activation loop. Once Erk1 and Erk2 are phosphorylated
they regulate the transcription of genes involved in a
range of fundamental cellular processes including cell
survival, proliferation, motility, and differentiation [5].
The two isoforms Erk1 and Erk2 share a high level of
amino acid identity (88%), are ubiquitously expressed in
mammalian cells, are coactivated in response to extracel-
lular stimuli [6,7] and recognize the same substrates
[8-11]. However various studies describe a nonredundant
function of Erk1 and Erk2. Analyses of mouse models
show that disruption of the Erk2 gene leads to early em-
bryonic lethality, while disruption of Erk1 does not
[12,13]. In vitro studies have also suggested that Erk1
and Erk2 may exert distinct functions in certain cellular
contexts. For example, a knockdown of Erk2 expression
restrains hepatocyte cell division, whereas Erk1 silen-
cing specifically improves long-term hepatocyte survivalntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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induces epithelial-to-mesenchymal transformation [16].
Other studies reported that osteosarcoma cells regulate
the expression of gp130 via Erk2 [17]. Furthermore it has
been reported that siRNA knockdown of Erk1 in fibro-
blasts enhances Erk2 signaling and results in enhanced cell
proliferation [18].
In our study we reveal an Erk2 dependent crosstalk be-
tween tumor stroma associated HGF/Met signaling and
tumor cell associated EGFR signaling. HGF is a frequently
detected ligand in the tumor stroma, mainly released by
tumor-associated macrophages (TAMs) and by stromal
fibroblasts [19-21]. Met receptor activation in cancer cells
upon HGF binding, was shown to trigger several pro-
tumorigenic pathways [22-25]. However, the complex
crosstalk between epithelial tumor cells and stromal cells
is yet poorly understood. Several studies have shown di-
verse mechanisms of transactivation between Met and the
EGF receptor family [26-34]: the hyperactivation of Met,
for example, was shown to play a role in resistance forma-
tion to EGF-receptor-family-blocking agents [26,27,32].Figure 1 The MAPK pathway regulates amphiregulin induction and a
amphiregulin protein synthesis. (A) Quantification of amphiregulin prote
release was assayed using sandwich ELISA. Error bars indicate SEM of three
induction. SCC9 cells were treated with 100 ng/ml HGF for the indicated ti
HPRT1 cDNA. Values are shown as mean ± SD (n = 2). (C) Quantification of
(D) Quantification of amphiregulin protein release. SCC9 cells were treated
(=CHX; 1 μg/ml) and geneticin (=G418; 1 mg/ml) for 24 h. Ligand release i
indicate SEM of three independent experiments. (E) Quantification of amph
MEK inhibitor UO126 and 50 nM of the PI3K inhibitor wortmannin (=W) for
protein release. SCC9 cells were pretreated for 15 min with UO126 and wo
independent experiments. Asterisks indicate statistically significant repressioScheving et al. demonstrated that inhibition of EGFR TK
blocks HGF-induced DNA synthesis in primary hepato-
cytes, indicating that the proliferative actions of HGF may
be secondary via new synthesis or processing of EGFR li-
gands [29]. Similarly, Spix et al. blocked HGF-induced
scattering of human corneal limbal epithelial cells with an
EGFR TK inhibitor [30]. Finally Reznik and coworkers
demonstrated that HGF stimulation of glioblastoma cells
induces EGFR activation via new transcription of EGFR
ligands [31].
Here, we attempted to specifically investigate the sig-
naling pathway underlying HGF/Met induced EGFR
ligand release in SCCs derived from different tissues.
Amphiregulin protein release upon HGF stimulation
could be observed in SCCs of the tongue, lung and
larynx (Figure 1A). In order to investigate which signal
transducer downstream of Met activation mediates the
upregulation of amphiregulin, we used, due to the high
amphiregulin production, SCC9 cells as a preliminary
model system. The amphiregulin transcript induction
peaked within the first two hours after HGF stimulationmphiregulin release upon HGF stimulation depends on
in release in different SCC cell lines treated with HGF for 24 h. Ligand
independent experiments. (B) Quantification of amphiregulin mRNA
me points. Data represent the increase of amphiregulin normalized to
amphiregulin protein release. Values are shown as mean ± SD (n = 2).
with 100 ng/ml HGF and with the translation inhibitors cycloheximide
nto the supernatant was assayed using sandwich ELISA. Error bars
iregulin mRNA induction. SCC9 cells were pretreated with 5 μM of the
15 min before 2 h HGF treatment. (F) Quantification of amphiregulin
rtmannin before 24 h HGF treatment. Error bars indicate SEM of three
n or induction (p < 0.05, paired t-test).
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after 4–8 hours and peaked after 24 hours (Figure 1C).
To test whether the amphiregulin release depends on
new protein synthesis or on shedding of existing pro-
forms, the effect of the translation inhibitors cyclohexi-
mide (=CHX) and geneticin (=G418) was investigated.
Both inhibitors abrogated amphiregulin release into the
supernatant, suggesting that amphiregulin release fully
depends on new protein synthesis (Figure 1D). Further-
more, SCC9 cells were incubated with inhibitors for
MEK and for PI3 kinase, prior to HGF stimulation.
mRNA levels of amphiregulin were measured after
2 hours and protein levels were measured after 24 hours
of stimulation. The inhibitor specificity and efficacy was
analyzed 5 minutes after HGF stimulation and is shown
in Additional file 1: Figure S1. Notably, full inhibition of
amphiregulin mRNA (Figure 1E) and protein (Figure 1F)
induction was achieved with the MEK inhibitor UO126,
while only a minor effect was observed with the PI3K
inhibitor at the protein level (Figure 1F). These experi-
ments prove the regulation on transcript level and reveal
a MAPK-pathway-dependent amphiregulin production.
Consistent with our previous findings, although the
EGFR ligand amphiregulin is present in the cell culture
medium, the EGF receptor does not become phosphor-
ylated on tyrosine residues after HGF treatment [32]
(Figure 2A). Therefore, in order to test if the released
amphiregulin is capable of activating EGFR, the follow-
ing two-step experiment was performed: first, SCC9
cells were stimulated with HGF. After 24 hours the
conditioned medium (=CM) was collected. Second,Figure 2 Amphiregulin is an activator of EGFR and HER2. The CM of a
cells. (A) EGFR IP followed by Western blot analysis of SCC9 cells treated w
Immunoblots for phospho-tyrosine (=pY) and EGFR are shown. Total cell ly
HER2 IP followed by Western blot analysis. SCC9 cells were stimulated for 5
antibody (=B-AR). The blocking antibody was added to the CM 30 min prio
The CM of the monocytic cell line MAD-NT induced HGF-dependent amph
when MAD-NT CM was pretreated with a HGF-blocking antibody (=B-HGF)
the Met inhibitor PHA-665752 (=PHA). Ligand release was assayed using sand
The asterisk indicate a statistically significant decrease (p < 0.05, paired t-test).
MAD-NT CM, MAD-NT CM plus a HGF-blocking antibody and of SCC9 cells pr
pAkt, pp38 MAPK and pErk1/2 are shown. Tubulin served as loading control.fresh, untreated SCC9 cells were stimulated for three
minutes with this CM, lysed and immunobloted for
phospho-tyrosine and EGFR. If active EGFR ligands
were shed, an activation of the EGFR should occur
now. Indeed, strong EGFR and HER2 phosphorylation
was observed and a blocking antibody experiment
(verification of antibody specificity in Additional file 2:
Figure S2) revealed amphiregulin to be the major con-
tributor of activation (Figure 2B).
Monocytes, macrophages and fibroblasts are thought
to be the major sources of HGF in the tumor stroma
[35-37]. It was of interest, whether a complex CM de-
rived from a monocytic cell line, is capable to induce
EGFR ligand release. Therefore, CM of MAD-NT cells, a
HGF producing subclone of the promyelocytic leukemia
cell line HL60, was used (Additional file 3: Figure S3).
Amphiregulin was released upon MAD-NT CM by
SCC9 cells and a HGF-blocking antibody as well as the
Met inhibitor PHA-665752 abrogated the amphiregulin
production (Figure 2C). The Met inhibitor efficacy was
analyzed 3 minutes after HGF stimulation and is shown
in Additional file 4: Figure S4. In the next step, SCC9
cells were stimulated for 10 minutes with HGF and with
MAD-NT CM and assayed in immunoblot analysis for
the activation of the downstream signal transducers
Erk1/2, Akt, p38 MAPK and SAPK/JNK. All tested sig-
nal transducers got activated by HGF and by MAD-NT
CM. Both, the HGF-blocking antibody as well as the
Met inhibitor PHA-665752 reduced activation of Erk1/2,
Akt, p38 MAPK and SAPK/JNK (Figure 2D). These data
indicate, that monocytes can be a major source of HGFmonocytic cell line induces the release of amphiregulin in SCC9
ith 100 ng/ml HGF for 24 h and with 10 ng/ml EGF for 3 min.
sate blotted with tubulin was used as loading control. (B) EGFR and
min with HGF CM in the presence of 5 μg/ml amphiregulin-blocking
r to stimulation. Immunoblots for pY, EGFR and HER2 are shown. (C)
iregulin release in SCC9 cells. Amphiregulin release was blocked, both
, as well as when SCC9 cells were pretreated for 30 min with 1 μm of
wich ELISA. Error bars indicate SEM of three independent experiments.
(D) Western blot analysis of SCC9 cells stimulated for 10 min with HGF,
etreated with the Met inhibitor PHA-665752. Immunoblots for pSAPK/JNK,
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ing cascades.
To evaluate which MAPK is responsible for the EGFR
ligand induction, siRNA knockdown experiments of Erk1
and Erk2 were performed. The CM of MAD-NT cells was
used as HGF source. A Knockdown of Erk2 dramatically
reduced the release of amphiregulin, whereas a knock-
down of Erk1 showed no effect. To exclude the possibility
of an off-target effect, two different siRNAs for Erk2 were
used. Similar results were obtained with both Erk2
siRNAs. Interestingly a double knockdown of Erk1 and
Erk2 further reduced the production of amphiregulin, in-
dicating that Erk1 could partly compensate for the loss ofFigure 3 Erk2 is required for HGF-induced amphiregulin production.
used as HGF source. For the Erk2 knockdown two siRNAs (Erk2#1 and Erk2#
(B) Erk2 siRNA knockdown in different SCC cell lines. Non-targeting siRNA w
sandwich ELISA. Error bars indicate SEM of three independent experiments
t-test). Knockdown was verified with Erk1/2 immunoblot. Tubulin served asErk2 (Figure 3A). Moreover Erk2 depletion blocks HGF
induced amphiregulin release in tongue-, lung- and
larynx-derived SCC cell lines. Notably, although in NCI-
H2882 cells an Erk2 knockdown dramatically reduced
basal amphiregulin production, HGF stimulation was still
able to augment amphiregulin release similar to baseline
levels (Figure 3B). Altogether these data suggest that in
different human SCCs the upregulation and release of
amphiregulin upon HGF stimulation is mediated via Erk2.
In this study we have shown that HGF is a strong
inducer of the EGFR ligand amphiregulin in different
SCC cell lines and that amphiregulin acts as a potent
activator of EGFR and HER2 in HGF untreated SCC9(A) Erk1 and Erk2 siRNA knockdown in SCC9 cells. MAD-NT CM was
2) were used. Knockdown was verified with Erk1/2 immunoblot.
as used as negative control. Amphiregulin release was measured with
. Asterisks indicate a statistically significant decrease (p < 0.05, paired
loading control.
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cannot be further activated by amphiregulin. Therefore
it is likely, that the produced amphiregulin is provided
for other cell types of the tumor stroma, which did not
get in contact with HGF before or amphiregulin is pro-
vided for cell types, where the EGFR is not blocked by
HGF. A second possibility is that amphiregulin might in-
duce the recruitment and proliferation of stromal cells
like endothelial cells and fibroblasts (Figure 4) which
promote tumor progression. Interestingly Amin et al.
compared tumor-associated endothelial cells and normal
endothelial cells and found that tumor-derived endothe-
lial cells express EGFR, HER2 and HER4, whereas their
normal counterparts express HER2, HER3 and HER4
[38]. As a consequence of the gain of EGFR and the loss
of HER3, tumor vasculature responds to EGFR ligands.
In their study they suggest that this receptor exchange
promotes tumor angiogenesis. Similarly Cascone et al.
showed in a mouse xenograft model of human lung
andenocarcinoma an upregulation and hyperactivation
of stromal EGFR in blood vessel pericytes of anti-VEGF
treatment resistant tumors. In this elegant study they
were able to distinguish between stromal (mouse) and
cancer (human) cell specific changes of total and of
phosphorylated EGFR levels [39]. Several other studies
show a proangiogenic and tumor supporting effect of
EGFR signaling inside the tumor vasculature [40,41]. A
third possibility is, that the tumor-produced EGFR
ligands exert their function in distant tissues andFigure 4 Paracrine interaction model between TAM, tumor cells
and endothelial cells. TAMs and tumor-associated stromal fibroblasts
release a variety of factors that support tumor growth and progression.
HGF, one of these factors, prompts tumor cells to produce the EGFR
ligand amphiregulin (AR). Importantly, once the tumor cells are activated
by HGF, their EGF receptor cannot be activated by EGFR ligands
anymore. However, tumor-associated endothelial cells express high
levels of EGFR and have been shown to respond to EGFR activation
[38,42,43]. Therefore, we propose, that the tumor vasculature represent a
possible target for the produced EGFR ligands.influence the generation of the metastatic niche. In this
study, we identified MAPK signaling as the underlying
pathway for new amphiregulin mRNA and protein syn-
theses. We intended to specifically inhibit Erk1 and 2 by
siRNA knockdown and could demonstrate that Erk2 but
not Erk1 is responsible for amphiregulin upregulation.
In addition we demonstrate the ability of a monocytic
cell line to induce amphiregulin release in a HGF/Met/
MAPK-dependent manner. Our study grants further
investigations which cell type in the tumor microenvir-
onment or in distant tissues benefits from the released
EGFR ligand amphiregulin during cancer progression.
The detailed understanding of stromal signaling may be
critical for the development of successful treatments and
for the improvement of combination regimens.Materials and methods
Cell culture
Human squamous cell carcinoma cell lines derived from
different tissues were as follows: tongue-derived SCC4,
SCC9 and SCC15, larynx-derived UM-SCC-17B and
lung-derived NCI-H2882 and HCC95. The acute pro-
myelocytic leukemia cell line HL-60 clone MAD-NT
(Macrophage differentiation, non-terminal) has under-
gone spontaneous differentiation into semiadherent cells
and was generated in our laboratory. This cell line has
been used due to its ability to spontaneously produce
high levels of HGF (Additional file 3: Figure S3). All cell
lines were obtained from the American Type Culture
Collection, except HCC95 and NCI-H2882 cells which
were a kind gift from Prof. Roman Thomas (University
of Cologne) and UM-SCC-17B cells which were a kind
gift from Prof. Thomas Wustrow (Ludwig-Maximilian-
University of Munich). The ligands and blocking anti-
bodies were purchased from R & D Systems. Geneticin
was from Invitrogen, UO126 was from Cell Signaling
Technologies, cycloheximide and Wortmannin were
from Sigma, PHA-665752 was from Biomol. The siRNAs
for Erk1 (cat# J-003592-10), Erk2#1 (cat# J-003555-12),
Erk2#2 (cat# J-003555-14) and the non-targeting siRNA
(cat# D-001810-03) were purchased from Dharmacon
and transfection was performed with Lipofectamine
RNAiMax (Invitrogen).
Quantitative RT-PCR
Total RNA was transcribed into complementary DNA
using First Strand cDNA Synthesis Kit (Fermentas).
SYBR Green Master Mix (Roche) was used for RT-qPCR
measurement. The used primers were: amphiregulin→
5′-TGGTGCTGTCGCTCTTGATA-3′, ← 5′-GCCAGG
TATTTGTGGTTCGT-3′; reference gene HPRT1→ 5′-
GCTATAAATTCTTTGCTGACCTGCTG-3′,← 5′-AA
TTACTTTTATGTCCCCTGTTGACTGG-3′.
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Amphiregulin and HGF protein was measured using
sandwich ELISA (R&D Systems).
Immunoblotting and immunoprecipitation
For immunoprecipitation 0.5 mg of total protein, 1 μg of
homemade monoclonal EGFR antibody (clone 108.1; has
been characterized before [44]) and 5 μg of monoclonal
HER2 antibody (clone 13D1B1; has been characterized
before [44]) together with 10 μl of protein A-sepharose
(GE Healthcare) were used. For the HGF immunopre-
cipitation 1 ml of HL60 and MAD-NT cell CM and 20
μg monoclonal HGF antibody (R&D Systems) together
with 15 μl of protein A-sepharose were used. For
immunoblotting the following antibodies were used:
p-tyrosine (homemade clone 4G10), pAkt S473 (Cell Sig-
naling Technologies), pErk1/2 T202/Y204 (Cell Signaling
Technologies), pSAPK/JNK T183/Y185 (Cell Signaling
Technologies), Erk1/2 (Santa Cruz Biotechnology), EGFR
(Cell Signaling Technologies), HER2 (Millipore), HGF
(R&D Systems), pMet Y1234/Y1235 (Cell Signaling
Technologies), pp38 T180/Y182 (Cell Signaling Tech-
nologies) and tubulin (Sigma).
Additional files
Additional file 1: Figure S1. Specificity and efficacy of MEK and PI3K
inhibitors. Western blot analysis of SCC9 cells incubated with the MEK
inhibitor UO126 and with the PI3K inhibitor wortmannin (=W) for 30 min
prior to stimulation with HGF for 5 min. Total cell lysates were
immunoblotted as indicated. Tubulin served as loading control.
Additional file 2: Figure S2. Specificity of amphiregulin-blocking
antibody. Western blot analysis of SCC9 cells treated with different EGFR
ligands, which were preincubated with a amphiregulin-blocking antibody
(R&D Systems) for 1 h before stimulation in a final concentration of
2.5 μg/ml. Total cell lysate was immunoblotted for pEGFR Y1173, EGFR
and tubulin. EGFR and tubulin served as loading controls.
Additional file 3: Figure S3. MAD-NT cells but not HL60 cells
spontaneously produce high levels of HGF. (A) Quantification of HGF
protein release into the supernatant of HL60 and MAD-NT cells after 24 h.
Error bars indicate SEM of three independent experiments. Ligand release
was assayed using sandwich ELISA. Asterisks indicate a statistically significant
increase (p < 0.05, paired t-test). (B) HGF IP followed by Western blot analysis
of HL60 and MAD-NT cell CM. An immunoblot for HGF is shown.
Additional file 4: Figure S4. Specificity of Met inhibitor. Western blot
analysis of SCC9 cells incubated with the Met inhibitor PHA-665752 for
30 min prior to stimulation with HGF for 3 min. Total cell lysates were
immunoblotted for pMet. Tubulin served as loading control.
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